Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ABMD - Replacement Heart System -- Ignore unavailable to you. Want to Upgrade?

To: Alan Brezin who wrote (88)	7/29/2001 9:53:27 AM
From: High-Tech East	Read Replies (2) \| Respond to of 147

good news from Boston Saturday July 28, 4:01 pm Eastern Time, Press Release ADVISORY/ ABIOMED Hosts Grand Rounds On First Human Implant of AbioCor Replacement Heart BOSTON--(BW HealthWire)--July 28, 2001--ABIOMED, Inc. (NASDAQ:ABMD - news) today held a day-long Grand Rounds in Boston with teams from the medical centers approved by the federal Food and Drug Administration to participate in the initial human trials of the AbioCor(TM) (pronounced ``AB'-EE-O-KOR'') Implantable Replacement Heart. The closed session, moderated by Dr. Mehmet C. Oz of Columbia University and New York's Columbia Presbyterian Hospital, was attended by representatives of all of the medical teams participating in the clinical trial as well as a small number of invited guests. Attendees received a detailed report on the first AbioCor implantation from Drs. Laman A. Gray and Robert D. Dowling of the University of Louisville and Jewish Hospital, who along with members of their surgical and medical team performed the first implant of the AbioCor heart in a human on Monday, July 2nd. Dr. Robert T. V. Kung, ABIOMED's Chief Scientific Officer, provided a detailed evaluation of the performance of the AbioCor system to date. Patient selection, post-surgical patient management and the progress of the first patient were also addressed. Dr. O.H. (Bud) Frazier of the Texas Heart Institute and St. Luke's Episcopal Hospital, who has been the principal clinical collaborator to ABIOMED throughout the development of the AbioCor heart, provided an invaluable link between the developmental and initial clinical stages of the program. Dr. Dowling, participated by video conference from Jewish Hospital in Louisville so that he could remain close to the patient. The patient himself also participated briefly in the session. ABIOMED Chairman and CEO, Dr. David M. Lederman remarked that the Grand Rounds ``provided an extraordinary forum for open and timely scientific and medical information-sharing with the medical teams that are integral to the success of the entire clinical trial.'' He added that ``similar sessions will continue to be scheduled periodically to insure timely peer discussion of vital clinical data prior to more formal presentations to be made at scheduled Medical Society meetings and submissions for publication in the appropriate medical journals.'' ``The medical teams selected for this trial and participating in the briefing are among the best in the world. We believe that it is important for them to carefully review, discuss, and learn from each other during this first implant and from all subsequent implants in this trial. Our goal has always been to share information about the clinical trial with the medical community while at the same time doing all that we can to protect patient privacy and confidentiality, patient care, and patient quality of life. We remain committed to these goals,'' said Dr. Lederman. biz.yahoo.com